Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash from Operations (2022 - 2025)

Atara Biotherapeutics' Cash from Operations history spans 4 years, with the latest figure at 5697000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 76.72% year-over-year to 5697000.0; the TTM value through Dec 2025 reached 50940000.0, up 25.87%, while the annual FY2025 figure was 50940000.0, 25.87% up from the prior year.
  • Cash from Operations reached 5697000.0 in Q4 2025 per ATRA's latest filing, up from 9787000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3989000.0 in Q3 2024 to a low of 84529000.0 in Q1 2022.
  • Average Cash from Operations over 4 years is 36441500.0, with a median of 34020500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: skyrocketed 92.23% in 2024, then tumbled 145.35% in 2025.
  • A 4-year view of Cash from Operations shows it stood at 56880000.0 in 2022, then rose by 11.38% to 50406000.0 in 2023, then skyrocketed by 51.45% to 24471000.0 in 2024, then surged by 76.72% to 5697000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Cash from Operations are 5697000.0 (Q4 2025), 9787000.0 (Q3 2025), and 7318000.0 (Q2 2025).